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tries, access to direct acting antiviral agents to treat HCV is
restricted to individuals with advanced liver disease (METAVIR
stage F3 or F4). Our goal was to estimate the long term impact
of deferring HCV treatment for men who have sex with men
(MSM) who are coinfected with HIV and often have multiple risk
factors for liver disease progression.
Methods:We developed an individual-based model of liver dis-
ease progression in HIV/HCV coinfected MSM. We estimated
liver-related morbidity and mortality as well as the median time
spent with replicating HCV infection when individuals were treated
in liver fibrosis stages F0, F1, F2, F3 or F4 on the METAVIR scale.
Results: The percentage of individuals who died of liver-related
complications was 2% if treatment was initiated in F0 or F1. It
increased to 3% if treatment was deferred until F2, 7% if it was
deferred until F3 and 22% if deferred until F4. Themedian time indi-
viduals spent with replicating HCV increased from 5 years if treat-
mentwas initiated inF2 to almost15 years if itwasdeferreduntil F4.
Conclusions: Deferring HCV therapy until advanced liver fibrosis
is established could increase liver-related morbidity and mortal-
ity in HIV/HCV coinfected individuals, and substantially prolong
the time individuals spend with a replicating HCV infection.Journal of Hepatology 20
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Liver disease has become a leading cause of mortality in people
who live with HIV (PWLH); it is often caused by infection with
the Hepatitis C virus (HCV) [1,2]. In high-income countries, about
30% of HIV-positive individuals are coinfected with HCV, though
the proportion varies by risk group. As many as 70–90% of HIV-
positive intravenous drug users are coinfected with HCV [3]. In
the population of HIV-positive men who have sex with men
(MSM) [4–6], HCV incidence has increased in recent years. The
accelerated fibrosis progression observed in some studies [7–9],
and the high incidence of HCV seroconversions and reinfections
underscore the need for reliable predictions of the HCV disease
burden and of the optimal therapeutic interventions in this pop-
ulation. Successful HCV treatment greatly reduces the risk of
decompensated cirrhosis, hepatocellular carcinoma (HCC) and
extrahepatic complications, but does not eliminate it [10–15].
Because HIV coinfected individuals have multiple risk factors
for liver disease, including drug toxicity and metabolic liver dis-
ease, they might be at increased risk to have liver-related compli-
cations even after they clear HCV [12,14,16]. We do not know if
treatment can be deferred until METAVIR stages PF3 without
increasing the risk of liver-related complications [17].
For the last decade, the standard of care for people infected
with HCV has been treatment with pegylated-interferon-a
(PegIFN) plus ribavirin (RBV). This interferon (IFN) -based regi-
men is challenging to use, especially in HIV coinfected individuals
who are at high-risk for serious side effects and have a low prob-
ability of cure [18–20]. Recently, new direct acting antivirals
(DAAs) have revolutionized the treatment of HCV. These16 vol. 65 j 26–32
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Fig. 1. Model structure. Individuals can progress vertically through the METAVIR
fibrosis stages (F0 to F4) and the endpoints: decompensated cirrhosis (DC) and
hepatocellular carcinoma (HCC). From any of those stages individuals can also
progress horizontally along the care cascade and be diagnosed, put onto
treatment, fail treatment or be cured. Individuals who clear HCV, either
spontaneously or because they succeeded treatment have undetectable HCV.
The rates of progression through the METAVIR stages depends on several factors
including whether the individual has undetectable HCV or not.
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compounds are very effective, easy to use, and have few con-
traindications. These are factors that greatly increase the propor-
tion of PWLH eligible for HCV treatment [21–24]. Yet the very
high cost of the DAAs represents a major barrier to widespread
treatment scale-up and is a matter of debate [25]. Although the
European Association for the Study of the Liver (EASL) now rec-
ommends that individuals coinfected with HIV are prioritized
for treatment regardless of their fibrosis stage [26], reimburse-
ment of HCV therapy is often restricted to individuals with
advanced liver fibrosis [17,27–29].
We set out to estimate the impact of deferring HCV treatment
on liver-related complications in HIV coinfected individuals by
using a model of liver disease progression and care. Our main
outcomes of interest were liver-related morbidity and mortality
as well as the time spent with replicating HCV.
Materials and methods
Data sources
We parameterized the model with data from the Swiss HIV Cohort Study (SHCS)
and published literature. The SHCS (www.shcs.ch) is a prospective cohort study of
PWLH that includes 73% of all diagnosed HIV-infections in Switzerland [30].
Detailed demographic, clinical and laboratory characteristics, HCV genotypes,
treatment rates, and estimated duration of HIV infection are collected at baseline
and during follow-up visits every six months.
Model structure and inputs
We developed the model using ‘gems’, an R package that enables the creation of
multistate models with generalized hazard functions [31,32]. Fig. 1 shows the
structure of the model, which is organized in two dimensions: progress of liver
disease and cascade of HCV care. We defined the stages of liver disease, from
healthy liver to compensated liver cirrhosis (F0-F4) based on the METAVIR scor-
ing system. Individuals in METAVIR stage F4 could progress to decompensated
cirrhosis or HCC. Progression from decompensated cirrhosis to HCC was also pos-
sible. At any disease stage, individuals were allowed to progress along the cascade
of care: they could be diagnosed, treated, and succeed or fail treatment. Individ-
uals could also spontaneously clear the infection. Death could occur in any state.
We present themodel’s input parameters in Supplementary Table 1. Simulated
individuals were assigned the following characteristics at time of HCV infection:
age, HCV genotype, and METAVIR stage (details in Supplementary material). We
derived the distribution of these characteristics from the SHCS dataset (Table 1).
When we calculated the HCV diagnosis rate, we assumed that individuals were
screened annually for HCV antibodies, with a sensitivity that increased from 25%
at time of HCV infection to 95% after one year [33], and that elevated liver enzymes
would reveal 88% of infections within the first three months of infection [33]. We
assumed the progress of liver disease was the same across the METAVIR stages,
and increased with older age at time of infection with HCV [34]. We assumed that
clearing HCV decreased the rate at which fibrosis progressed from F0 to F4 (rate
ratio RR = 0.1), from F4 to decompensated cirrhosis (RR = 0.1), and from F4 to
HCC (RR = 0.38) [10] (details in Supplementary material). The probability of spon-
taneously clearing HCV followed a logistic decrease over a year, with an overall
probability of 32%. Treatment rates and outcomes differed across scenarios.
We modelled one baseline scenario (‘‘SHCS scenario”) and 5 interventions
(‘‘DAA scenarios”). The SHCS scenario was designed to reproduce current practice
in the SHCS before second generation DAAs were introduced. Individuals were
treated with PegIFN/RBV. Those with chronic HCV genotype 1 infection also
received a first generation DAA. We assumed that adding a first generation
DAA (telaprevir, boceprevir or faldaprevir) to PegIFN/RBV increased the probabil-
ity of treatment success in chronic infection (RR = 2.17) [35]. The probability of
treatment success followed a logistic decrease from 0.9 at the time of HCV
infection to the genotype-dependent probabilities described for chronic HCV
two years after (details in Supplementary material). Treatment response rates
were lower in people who had compensated cirrhosis than in non-cirrhotic
people (RR = 0.74) [36].
In our DAA scenarios, all diagnosed individuals were treated with second gen-
eration DAAs; the probability of treatment success differed by HCV genotypes and
cirrhosis status (Supplementary Table 1). We modelled five scenarios, in which
individuals were treated when they reached METAVIR stages F0, F1, F2, F3 or F4.Journal of Hepatology 20Model outcomes
The clinical outcomes of the model were cirrhosis, decompensated cirrhosis, HCC,
liver-related deaths, and time spent with replicating HCV.Sensitivity analysis
The uncertainty around the key parameter, the fibrosis progression rate by age at
HCV infection (Supplementary Table 1), was taken into account in the main anal-
ysis by sampling these parameters from a multivariate normal distribution. To
assess the robustness of our main results, we investigated the effect of modifying
our assumptions on the following parameters: progression of liver fibrosis
between F0 and F4 before and after HCV clearance, and progression from F4 to
the outcomes (details in Supplementary material).
The impact of HCV reinfections was assessed by building an alternative
model. In this model we assumed that either 9% of the individuals who had
cleared an HCV infection were reinfected after a median time of 3.3 year as
observed in the SHCS [37], or that 22% were reinfected after a median time of
2.1 years as described by Martin et al. [38]. In these scenarios, reinfected individ-
uals were not retreated in order to obtain an estimate of the ‘‘worst-case-
scenario”.Cost calculations
We calculated the cost per 100 HCV infections in our five DAA scenarios by add-
ing the cost of disease stages to the treatment costs. We estimated the mean
patient cost by disease stage based on data collected at the University Hospital
Zurich, Switzerland. The data included the whole population of HCV infected indi-
viduals (not only HIV coinfected). We used the cost of a 12-week course regimen
with sofosbuvir + ledipasvir in Switzerland.16 vol. 65 j 26–32 27
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Fig. 2. The SHCS (Swiss HIV cohort study) scenario. (A) Cumulative incidence of
any METAVIR fibrosis stages (F0-F4), decompensated cirrhosis (DC) and hepato-
cellular carcinoma (HCC) over time. (B) Percentage of individuals who experience
F4, DC, HCC over their lifetime or die of liver-related complications.
Table 1. Characteristics at HCV diagnosis.
Characteristic at HCV diagnosis Value Reference
Median age in years (IQR) 34 (21-47)i SHCS data
Duration of HIV infection in years (%) SHCS data
≤5 32.7
6-10 26.2
11-15 18.7
16-20 16.8
>20 5.6 
Median CD4 cells/μl (IQR)ii 459 (320-649) SHCS data
With suppressed HIV RNA (%)ii 81
HCV genotype (%) [5]
1 66.7
2 1.6
3 12.7
4 19.0
METAVIR stage at HCV infection (%) Simulated using 
duration of HIV 
infection and RR 
of liver fibrosis 
progression (see 
appendix for 
details)
F0 85.9
F1 15.1
F2 1.8
F3 0.2
F4 0.02
iModelled with a Weibull probability density function of the form f ¼ jk t
j1
k e
tjk
with j = 4.23 and k = 40.22.
iiNot used in the model.
SHCS, Swiss HIV Cohort Study; IQR, Interquartile range.
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The SHCS scenario
This scenario is based on current HCV treatment strategies prior
to the availability of second generation DAAs. We estimate that
46% of the simulated HIV/HCV infected individuals developed
liver cirrhosis over their lifetime, 11% experienced decompen-
sated cirrhosis and 17% HCC (Fig. 2). Of the simulated individuals
27% died of liver-related causes, and 0.8% died of liver-related
complications after they cleared HCV.
The second generation DAAs scenarios
The effect of deferring HCV treatment until later stages of liver
fibrosis is shown in Fig. 3A. The percentage of simulated individ-
uals who died of liver-related complications was 2% if treatment
was initiated in F0 or in F1. It rose to 3% if treatment was deferred
until F2, 7% if deferred until F3, and 22% if deferred until F4.
Less than 1% died after clearing HCV if they were treated as
they reached F0 or F1. This percentage increased to 2% if treat-
ment was deferred until F2, 6% if it was deferred until F3, and
17% if it was deferred until F4 (Fig. 3B). A large proportion of
liver-related deaths occurred in individuals without replicating
HCV if treatment was deferred until advanced fibrosis or cirrhosis
as the model assumed that SVR substantially reduces the risk of
liver disease progression but does not eliminate it [10–15]. The
median time spent with replicating HCV increased from 5 years
if treatment was initiated in F2 to almost 15 years if treatment
was deferred until F4 (Fig. 4). The percentages of individuals
who died from liver-related complications depending on the28 Journal of Hepatology 20follow-up time since HCV infection are shown in Supplementary
Table 2.
Sensitivity analysis
Supplementary Fig. 1 shows the impact of varying the key input
parameters on the percentage of individuals who die of liver-
related complications. Our base analysis is the one described
above (all 5 DAA scenarios). Results are described in the appen-
dix. The claim that early treatment can prevent liver-related
deaths was true in most analyses, unless we assumed an extre-
mely high rate of fibrosis progression (Supplementary Fig. 1E),
or that liver disease never progressed after HCV was cleared
(Supplementary Fig. 1B).
Supplementary Figs. 2 and 3 show the impact of HCV reinfec-
tions. Assuming that 9% of the individuals who cleared HCV infec-
tion were reinfected [37], the difference in the proportion of
liver-related deaths between the different scenarios was lower
compared to the base scenarios. The percentage of individuals
who died of liver-related complications was 7% if individuals
were treated in METAVIR stage F0 or F1 and 8% if they were trea-
ted in F2. It increased to 12% if treatment was deferred until F3
and to 26% if it was deferred until F4. When we assumed that
22% experienced a reinfection as observed by Martin et al. [38],
the percentage of individuals who died of liver-related
complications was 15% if individuals were treated in F0, F1 or
F2. It increased to 18% if treatment was deferred until F3 and to
30% if it was deferred until F4.16 vol. 65 j 26–32
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Fig. 3. The DAA scenarios. (A) Impact of deferring HCV treatment on liver-
related complications. The figure shows the percentage of individuals who
experience cirrhosis (F4), decompensated cirrhosis (DC), hepatocellular carci-
noma (HCC) and liver-related deaths for different treatment scenarios. (B)
Percentage of individuals who die of liver-related complications with or without
replicating HCV infection. F0-F4: METAVIR fibrosis stages.
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Fig. 4. Median years with replicating HCV infection. Data by treatment
scenario.
JOURNAL OF HEPATOLOGYCost calculations
The total cost, including disease and treatment costs, per
100 HCV infections varied between 4.8 and 5.9 million Euros,Journal of Hepatology 20depending on the timing of HCV treatment (Supplementary
Table 3; details in Supplementary material).Discussion
Principal findings
Over a lifetime, deferring HCV treatment until advanced liver dis-
ease stages is likely to substantially increase liver-related compli-
cations, increase the time individuals spend with replicating HCV,
and may not save money.
In many settings, cost considerations and related limitations
in reimbursement by health insurances have led the authorities
to recommend that HCV treatment be deferred until METAVIR
stage F3 or more. Our model showed that in HIV positive MSM,
initiating HCV therapy in METAVIR stage F2 instead of deferring
treatment until stage F3 or F4 could prevent 4-19 liver-related
deaths per 100 HCV infections. In the scenario where all diag-
nosed individuals are treated with DAAs in METAVIR stages F3
or F4, most liver-related deaths were caused by liver disease pro-
gression after HCV clearance, rather than because of treatment
failure or a lack of diagnosis. Thus, if treatment is deferred until
advanced fibrosis or cirrhosis has developed, most liver-related
deaths will occur after HCV is cleared. HCV clearance is often
associated with fibrosis regression, but liver fibrosis may progress
in some individuals after HCV clearance [10,12,16,17,39–42].
Accordingly, deferring treatment until advanced fibrosis
increased liver-related morbidity and mortality in all scenarios
except when we assumed that liver fibrosis never progressed
after SVR, or in a scenario with an extremely fast fibrosis progres-
sion. This is plausible since many risk factors associated with
fibrogenesis, including drug toxicity, alcohol use, coinfections or
metabolic liver disease, persist after cure. HCC can occur in those
with cirrhotic livers even after they clear HCV [10]. Reinfections
have been observed in up to 22% of patients following sponta-
neous or treatment-induced HCV clearance [38]. As expected,
the benefit of treating individuals earlier was partially offset
through reinfections and the proportion of patients who experi-
enced liver-related events was higher if reinfections were consid-
ered (Supplementary Figs. 2 and 3). However, even in a worst-
case-scenario assuming a very high reinfection rate and no
retreatment, treating earlier reduced liver-related complications.
We show that initiating HCV therapy in F2, instead of F3 or F4,
reduced the time individuals spent with replicating HCV by 47–
64% as compared to when therapy is started in F1. Initiating ther-
apy in F1, instead of waiting until F3 or F4 reduced the median
time spent with replicating HCV by 85–90%. Early treatment
reduced the median time with replicating HCV even in our
worst-case-scenario where reinfected individuals were not
retreated. This may decrease the risk of further HCV transmission
in those with high-risk behavior. This is particularly important
for HIV-positive MSM since this population is in the midst of an
increase in HCV transmissions. Earlier initiation of treatment
could be a valuable preventive strategy, akin to the concept of
treatment-as-prevention in HIV, which was established as a very
effective measure to reduce HIV transmissions [43]. A recent
study in the SHCS found that increased treatment uptake and
efficacy can reduce the proportion of individuals with replicating
HCV infection [37].
Our cost calculations suggest that, despite the very high cost
of treatment, early treatment might not increase total spending,16 vol. 65 j 26–32 29
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since the increase in treatment cost is balanced by the savings in
health care costs. This is assuming that prices of DAA therapy do
not decrease in the coming years.
Comparison with other studies
Three other studies modelled the effect of timing of HCV therapy.
The first investigated the effect of deferring HCV therapy in HCV
genotype 1 monoinfected individuals [44]. Researchers compared
the cost-effectiveness of initiating therapy in different stages of
liver disease and found it did not have much impact on the life
expectancy. The second study examined the cost-effectiveness
of early HCV treatment for individuals with HCV monoinfection
and concluded that treating those with moderate or advanced
fibrosis was cost-effective; the cost-effectiveness of treating
those with minimal or no fibrosis depended on the cost of treat-
ment [45]. The third study estimated the quality-adjusted life-
years (QALY) for a 40 years old patient to increase from 23.9 if
treatment was started in F4 to 33.7 if treatment started in F0
assuming and SVR rate of 90% [46]. These studies considered only
cohorts of HCV monoinfected individuals. The first study
assumed that successful HCV treatment would eliminate further
risk of liver disease progression, the second and the third studies
assumed that only individuals treated in F4 were still at risk of
liver disease progression after HCV clearance. In contrast, our
model assumes that liver fibrosis progresses in some individuals
[13,14,16,40], which led to an increase in liver-related events if
therapy was deferred until F3.
Of note, a recent cost-effectiveness analysis among HIV/HCV
coinfected patients suggested that IFN-free regimens will be
cost-effective if treatment costs were below 109’000 USD, which
is now the case in many settings [47]. For the Swiss setting, a
recent study suggested that DAA-based therapies were cost-
effective even at current prices if a threshold of 100,000 CHF
per QALY was assumed [48]. Another study published in 2015
demonstrated that cost-effectiveness is highly sensitive to drug
prices and that treating patients in F0 would be cost-effective if
treatment costs were below 50’000 USD [49]. A recent study
[50] showed that the life expectancy of HCV monoinfected indi-
viduals who had been successfully treated in an advanced liver
disease stage was comparable to that of the general population.
The apparent inconsistency between this finding and our results
can be explained by the differences between the cohorts, includ-
ing different patient characteristics and very different follow-up
times. The median follow-up time in that study was 8.4 years,
while we make predictions over a lifetime. In fact, when we sim-
ulated a cohort of individuals cured in an advanced stage of the
disease, our model predicted a very low percentage (1.2%) of
liver-related deaths after 8.4 years of follow-up (see Supplemen-
tary material). A recent meta-analysis [10] estimated a 5-year
risk of HCC after SVR of 2.9% in the overall population, and 5.3%
among cirrhotic individuals.
Strengths and limitations
Our study was strengthened by our access to observed data from
a large and nationally representative cohort of PWLH. Data were
collected prospectively during regular follow-up visits and
include detailed demographic, clinical and laboratory data on
HIV and HCV infections. The individual-based design of our
model enabled us to exploit this detailed information. The use30 Journal of Hepatology 20of the R package ‘gems’ allowed us to model time-dependant
transition rates for spontaneous HCV clearance and treat-
ment success. The very flexible structure of the model also
allowed us to adapt parameters quickly as new data became
available.
Our study also has several limitations. First, we derived some
input parameters from the literature, which implies heterogene-
ity in both data collection and reporting. Second, the results apply
primarily to HIV-positive MSM and might not be generalizable to
HIV-positive people who acquired HCV through injecting drug
use with different demographic and clinical characteristics. Third,
disease-costs for each fibrosis stage were calculated as total
health care costs excluding treatment as described before [51].
As these costs include potential costs due to IFN-related side
effects, the disease stage costs could overestimate the true costs
in the interferon-free DAA era. Fourth, cost calculations are highly
dependent on the future developments in DAA prices and differ
substantially between countries and recommended regimens.
Therefore, cost estimates from this study might not be applicable
to other settings. Fifth, the costs averted by preventing complica-
tions after secondary HCV infections was not considered, leading
to an underestimation of the benefit of early treatment on costs.
Sixth, we did not explicitly model that, after cure, liver fibrosis
regresses in some individuals while it progresses in others
[12,39–41]. We instead used an average between individuals
who continue to have liver fibrosis progression, those who
remain stable, and those who regress their fibrosis, correspond-
ing to a tenfold reduction in fibrosis progression after HCV clear-
ance. Given published data on liver disease progression in both
HIV-monoinfected individuals, as well as in HIV/HCV coinfected
individuals after SVR, this is a conservative estimate of the risk
of liver disease progression after HCV clearance. Seventh, we
did not consider possible discrepancies between the measured
and the real stage of liver disease, though we are aware that
non-invasive diagnostic tools are not ideal predictors of liver
fibrosis [52]. People classified as F3 could already be cirrhotic,
but this is only an additional argument against deferring HCV
therapy. Eighth, in the SHCS scenario, we did not model explicitly
the side effects of IFN-based treatment. However, to some extent
this was accounted for by the lower cure rates in the SHCS if side
effects were present. Ninth, the impact of resistant variants
emerging after relapse on the effectiveness of DAA therapies
could not be investigated with the present model.
Implications of findings
Deferring HCV therapy until advanced liver fibrosis is established
may increase the percentage of liver-related complications in
people who have multiple risk factors for liver disease progres-
sion, such as HIV coinfected MSM. Our model predicts that the
time individuals spend with replicating HCV can be greatly short-
ened by early treatment. This may decrease further HCV trans-
missions in those with high-risk behavior. Both findings
support arguments that HCV therapy should be accessible to
everyone at an early stage. To make this affordable for health
insurances and governments, the costs for DAA drugs need to
be lowered substantially. Our findings support current recom-
mendations to start HCV treatment irrespective of fibrosis stage
in those with risk factors for accelerated fibrosis progression
including HIV coinfected MSM, and in persons at elevated risk
of HCV transmission [26].16 vol. 65 j 26–32
JOURNAL OF HEPATOLOGY
Financial support
This study has been financed within the framework of the Swiss
HIV and Hepatitis C Cohort Studies, supported by the Swiss
National Science Foundation (SNF grant #148522, #146143 and
#148417). Additional funding for this study came from Cancer
Research Switzerland (grant #2938-02-2012) and IeDEA South-
ern Africa (grant #U01AI069924). The funders had no role in
study design, data collection, data analysis, data interpretation,
writing of the report, and in the decision to submit the article
for publication. All authors declare that they are independent
from their funders. All authors had full access to all of the data
in the study and can take responsibility for the integrity of the
data and the accuracy of the data analysis.Conflict of interest
AR reports honoraria for advisory boards and/or travel grants
from Janssen-Cilag, MSD, Gilead Sciences, Abbvie, and Bristol-
Myers Squibb, and an unrestricted research grant from Gilead
Sciences, all remuneration went to his home institution and not
to AR personally, and all remuneration was provided outside
the submitted work. BM reports grants and personal fees from
Gilead, personal fees from Abbvie, personal fees from BMS,
personal fees from Roche, personal fees from MSD, personal fees
from Janssen, personal fees from Boehringer Ingelheim, outside
the submitted work. OK and BB received an unrestricted grant
from Gilead outside the submitted work. JE, JFD and GW have
nothing to disclose. There are no other relationships or activities
that could appear to have influenced the submitted work.Authors’ contributions
CZ, JE, AR and OK designed the study. CZ and LS formulated the
model. CZ, RK and GW analysed the cohort data. CZ performed
the model analyses. BB, JFD, BM contributed cohort data and
enrolled patients. All authors contributed to the interpretation
of the data and results. CZ, AR and OK drafted the manuscript,
which was then revised by all the other authors. CZ is the
guarantor.
Acknowledgements
We thank Kali Tal for her editorial assistance. This study has been
approved by all local ethical committees of the SHCS. The data are
gathered by the five Swiss University Hospitals, two Cantonal
Hospitals, 15 affiliated hospitals and 36 private physicians (listed
in http://www.shcs.ch/180-health-care-providers). Members of
the Swiss HIV Cohort Study: Aubert V, Battegay M, Bernasconi
E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M,
Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman
of the Clinical and Laboratory Committee), Fux CA, Gorgievski M,
Günthard H (President of the SHCS), Haerry D (deputy of ‘‘Posi-
tive Council”), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert
C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber
B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal
D, Nicca D, Pantaleo G, Rauch A (Chairman of the Scientific
Board), Regenass S, Rickenbach M (Head of Data Centre), Rudin
C (Chairman of the Mother & Child Substudy), Schöni-Affolter F,
Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A,
Vernazza P, Weber R, Yerly S.Journal of Hepatology 20Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhep.2016.02.
030.References
[1] Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors
associated with specific causes of death amongst HIV-positive individuals in
the D:A:D Study. Aids 2010;24:1537–1548.
[2] Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al.
Decreasing mortality and changing patterns of causes of death in the Swiss
HIV Cohort Study. HIV Med 2013;14:195–207.
[3] CDC. HIV and viral hepatitis, [accessed on 02.02.2014] http://www.cdc.gov/
hiv/pdf/library_factsheets_HIV_and_viral_Hepatitis.pdf; 2014.
[4] Hagan H, Neurer J, Jordan AE, Des Jarlais DC, Wu J, Dombrowski K, et al.
Hepatitis C virus infection among HIV-positive men who have sex with men:
protocol for a systematic review and meta-analysis. Syst Rev 2014;3:31.
[5] Wandeler G, Gsponer T, Bregenzer A, Gunthard HF, Clerc O, Calmy A, et al.
Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving
epidemic. Clin Infect Dis 2012;55:1408–1416.
[6] van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al.
Evidence of a large, international network of HCV transmission in HIV-
positive men who have sex with men. Gastroenterology
2009;136:1609–1617.
[7] Vogel M, Page E, Boesecke C, Reiberger T, Schwarze-Zander C, Mauss S, et al.
Liver fibrosis progression after acute hepatitis C virus infection in HIV-
positive individuals. Clin Infect Dis 2012;54:556–559.
[8] Osinusi A, Kleiner D, Wood B, Polis M, Masur H, Kottilil S. Rapid development
of advanced liver fibrosis after acquisition of hepatitis C infection during
primary HIV infection. AIDS Patient Care STDS 2009;23:403–406.
[9] Fierer DS, Dieterich DT, Fiel MI, Branch AD, Marks KM, Fusco DN, et al. Rapid
progression to decompensated cirrhosis, liver transplantation, and death in
HIV-infected men after primary HCV infection. Clin Infect Dis
2012;56:1038–1043.
[10] Hill AM, Saleem J, Heath KA, Simmons B. Effects of Sustained Virological
Response (SVR) on the risk of liver transplant, hepatocellular carcinoma,
death and re-infection: meta-analysis of 129 studies in 23,309 patients with
Hepatitis C infection. Hepatology 2014;60:55A.
[11] van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al.
Association between sustained virological response and all-cause mortality
among patients with chronic hepatitis C and advanced hepatic fibrosis.
JAMA 2012;308:2584–2593.
[12] Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C,
et al. Changes in liver fibrosis in HIV/HCV-coinfected patients following
different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat
2014;21:475–479.
[13] Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE,
et al. Excess liver-related morbidity of chronic hepatitis C patients, who
achieve a sustained viral response, and are discharged from care. Hepatology
2011;54:1547–1558.
[14] Mendeni M, Foca E, Gotti D, Ladisa N, Angarano G, Albini L, et al.
Evaluation of liver fibrosis: concordance analysis between noninvasive
scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-
infected patients without hepatitis C and B infection. Clin Infect Dis
2011;52:1164–1173.
[15] Chaudhry AA, Sulkowski MS, Chander G, Moore RD. Hazardous drinking
is associated with an elevated aspartate aminotransferase to platelet
ratio index in an urban HIV-infected clinical cohort. HIV Med
2009;10:133–142.
[16] Labarga P, Fernandez-Montero JV, de Mendoza C, Barreiro P, Pinilla J, Soriano
V. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-
HCV-coinfected patients. Antivir Ther 2014;20:329–334.
[17] Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, et al.
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients
treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Clin Infect Dis 2008;46:768–774.
[18] Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int
2013;33:63–67.
[19] Sulkowski MS. Current management of hepatitis C virus infection in patients
with HIV co-infection. J Infect Dis 2013;207:S26–S32.16 vol. 65 j 26–32 31
Research Article
[20] Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, et al. Optimizing
treatment in HIV/HCV coinfection. Dig Liver Dis 2013;45S5:S355–S362.
[21] Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a
systematic review. JAMA 2014;312:631–640.
[22] Martel-Laferriere V, Dieterich DT. Treating HCV in HIV 2013: on the cusp of
change. Liver Int 2014;34:53–59.
[23] Rockstroh JR, Bhagani S. Managing HIV/hepatitis C co-infection in the era of
direct acting antivirals. BMC Med 2013;11:234.
[24] Zeremski M, Martinez AD, Talal AH. Editorial commentary: Management of
hepatitis C Virus in HIV-infected patients in the era of direct-acting
antivirals. Clin Infect Dis 2014;58:880–882.
[25] Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing
hepatitis C direct-acting antivirals for use in large-scale treatment access
programs in developing countries. Clin Infect Dis 2014;58:928–936.
[26] EASL recommendations on treatment of hepatitis C 2015. J Hepatol
2015;63:199–236.
[27] Anthem Health Insurance. [accessed the 23.01.2015 https://www.an-
them.com/provider/noapplication/f0/s0/t0/pw_e210963.pdf?na=pharminfo;
2015.
[28] Moradpour D, Rauch A, Fehr J, Müllhaupt B. Treatment of chronic hepatitis
C- September 2014 Update. http://www.sginf.ch/ssi/images/ssi/news/SASL-
SSI_HepC_EOS_Sept2014.pdf; 2014.
[29] NICE. Sofosbuvir for treating chronic hepatitis C. https://www.nice.org.uk/
guidance/ta330; 2015.
[30] Kohler P, Schmidt AJ, Cavassini M, Furrer H, Calmy A, Battegay M, et al. The
HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for
patients diagnosed with HIV. AIDS 2015;29:2509–2515.
[31] Luisa Salazar Vizcaya NB, Thomas Gsponer. gems: Generalized multistate
simulation model. CRAN, R archive: http://cranr-projectorg/web/packages/
gems/indexhtml; 2014.
[32] Blaser N, Salazar Vizcaya L, Estill J, Zahnd C, Kalesan B, Egger M, et al. Gems:
an R package for simulating from disease progression models. J Stat Software
2015;64:1–22.
[33] Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, et al.
Delayed anti-HCV antibody response in HIV-positive men acutely infected
with HCV. Aids 2009;23:89–93.
[34] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression
in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and
DOSVIRC groups. Lancet 1997;349:825–832.
[35] Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir
versus placebo with pegylated interferon alfa-2b and ribavirin for treatment
of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-
blind, controlled phase 2 trial. Lancet Infect Dis 2013;13:597–605.
[36] Mira JA, Garcia-Rey S, Rivero A, de los Santos-Gil I, Lopez-Cortes LF, Giron-
Gonzalez JA, et al. Response to pegylated interferon plus ribavirin among
HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Clin Infect Dis 2012;55:1719–1726.
[37] Wandeler G, Schlauri M, Jaquier M-E, Rohrbach J, Mtzner KJ. Incident
hepatitis C Virus infections in the swiss HIV cohort study: changes in
treatment uptake and outcomes between 1991 and 2013. Open Forum Infect
Dis 2015;2:ofv026.32 Journal of Hepatology 20[38] Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al.
HCV reinfection incidence and treatment outcome among HIV-positive MSM
in London. Aids 2013;27:2551–2557.
[39] Lee YA, Friedman SL. Reversal, maintenance or progression: What happens
to the liver after a virologic cure of hepatitis C? Antiviral Res
2014;107C:23–30.
[40] Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-
Hatem D, et al. Eradication of hepatitis C virus in patients successfully
treated for chronic hepatitis C. Gastroenterology 2008;135:821–829.
[41] Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al.
Slow regression of liver fibrosis presumed by repeated biomarkers after
virological cure in patients with chronic hepatitis C. J Hepatol
2013;59:675–683.
[42] Casado JL, Quereda C, Moreno A, Perez-Elias MJ, Marti-Belda P, Moreno S.
Regression of liver fibrosis is progressive after sustained virological response
to HCV therapy in patients with hepatitis C and HIV coinfection. J Viral Hepat
2013;20:829–837.
[43] Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy
N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N
Engl J Med 2011;365:493–505.
[44] Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP,
et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-
naive patients? A cost-effectiveness analysis (ANRS 12188). J Hepatol
2014;61:7–14.
[45] Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-
effectiveness of hepatitis C treatment for patients in early stages of liver
disease. Hepatology 2015;61:1860–1869.
[46] McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, et al.
Estimating the clinical and economic benefit associated with incremental
improvements in sustained virologic response in chronic hepatitis C. PLoS
One 2015;10 e0117334.
[47] Linas BP, Barter DM, Leff JA, Dilorenzo M, Schackman BR, Horsburgh CR, et al.
The cost-effectiveness of improved hepatitis C virus therapies in HIV/
hepatitis C virus coinfected patients. Aids 2014;28:365–376.
[48] Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Mullhaupt B, et al. Cost-
effectiveness analysis of sofosbuvir compared to current standard treat-
ment in Swiss patients with chronic hepatitis C. PLoS One 2015;10
e0126984.
[49] Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-
effectiveness, health benefits, and financial costs of new antiviral treatments
for hepatitis C virus. Clin Infect Dis 2015;61:157–168.
[50] van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE,
et al. Life expectancy in patients with chronic HCV infection and cirrhosis
compared with a general population. JAMA 2014;312:1927–1928.
[51] Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al.
Modeling the health and economic burden of hepatitis C virus in Switzer-
land. PLoS One 2015;10 e0125214.
[52] Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of
hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.
Am J Gastroenterol 2007;102:2589–2600.16 vol. 65 j 26–32
